<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172377</url>
  </required_header>
  <id_info>
    <org_study_id>NL58948.091.16</org_study_id>
    <secondary_id>848015002</secondary_id>
    <secondary_id>2016-003321-42</secondary_id>
    <nct_id>NCT03172377</nct_id>
  </id_info>
  <brief_title>Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients</brief_title>
  <acronym>LADI</acronym>
  <official_title>Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease is a chronic inflammatory bowel disease. This disease can be treated with,
      among other things, biologicals such as adalimumab. Patients use adalimumab for a long time
      to maintain remission and to prevent relapse of the bowel inflammation. The disadvantages of
      this therapy are the high price and side effects (such as the higher risk of infection).

      Currently, adalimumab is given every 2 weeks, by injection under the skin. The optimal time
      between two injections has never been investigated before. Prior research in patients with
      rheumatoid arthritis shows that disease remission can be maintained with longer
      injection-intervals. Our hypothesis is that this is the same for Crohn's disease patients.
      Our aim is to show non-inferiority of extending the adalimumab dosing interval, under strict
      disease monitoring in Crohn's disease patients in sustained (&gt;9 months) clinical remission,
      compared to standard care.

      During the trial,174 patients with stable Crohn's disease will be divided into 2 groups. One
      group continues adalimumab injections with the same 2-week interval. And the other group will
      incrementally extend the interval to 4 weeks, under strict disease monitoring. If a step-down
      leads to recurrence of disease activity patients will return to the preceding effective
      dosing interval. Thus, we will investigate whether, and for whom, it is safe to extend the
      adalimumab injection interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale

      Adalimumab is both an effective induction and maintenance therapy for Crohn's disease (CD).
      Due to the risk of side effects (infections, injection reaction) and high costs, an extension
      of the injection interval is an attractive option. However, this strategy has not been
      evaluated yet in a randomized controlled trial in CD patients.

      Objective

      To assess non-inferiority and cost-effectiveness of disease activity guided adalimumab
      interval lengthening in CD patients in sustained (&gt;9 months) clinical remission, compared to
      standard dosing of every other week.

      Study design

      Multicenter, randomized controlled, open label non-inferiority trial, with two treatment
      arms.

      Study population

      Crohn's disease patients, in sustained clinical remission on adalimumab maintenance therapy.

      Intervention

      Intervention arm: The adalimumab injection interval during maintenance therapy (40 mg per 2
      weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and
      subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease
      activity patients will return to the preceding effective dosing interval.

      Control arm: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks.
      Treatment decisions are made at the discretion of the treating physician.

      Main study parameters/endpoints

      Primary outcome: Cumulative incidence of persistent disease flares in 48 weeks of follow-up.
      A persistent flare is defined as two of three of the following criteria persisting for &gt; 8
      weeks, despite dose escalation of adalimumab; FC &gt;250 µg/g, CRP≥10 mg/L, HBI ≥5.
      Non-inferiority is reached if the difference in cumulative incidence of persistent flares not
      exceeds the non-inferiority margin of 15%.

      Secondary outcomes include cumulative incidence of transient flares, adverse events,
      predictors for successful dose reduction and cost-effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized controlled, open label non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of persistent disease flares.</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>A persistent flare is defined as two of three of the following criteria persisting for &gt; 8 weeks, despite dose escalation of adalimumab; FC &gt;250 µg/g, CRP≥10 mg/L, HBI ≥5. Non-inferiority is reached if the difference in cumulative incidence of persistent flares not exceeds the non-inferiority margin of 15%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transient disease flares.</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>A transient flare is defined as two of three of the following criteria persisting for ≤ 8 weeks; FC &gt;250 µg/g, CRP≥10 mg/L, HBI ≥5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) adverse event rate</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>(Serious) adverse events that are (possibly) related to adalimumab and the (Serious) adverse events that are (possibly) related to adalimumab interval lengthening in the intervention and control group, expressed as events/ 100 patient-years of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether adalimumab drug level is associated with successful interval lengthening</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>Adalimumab drug levels at baseline measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether biochemic FC or CRP are associated with successful interval lengthening</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>Fecal calprotectin (mg/kg) or C-reactive protein (mg/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether co-medication use is associated with successful interval lengthening</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>Co-medication includes azathioprine, Co-medication includes azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decremental cost effectiveness ratio of this interval lengthening strategy</measure>
    <time_frame>From the date of randomization up to week 48.</time_frame>
    <description>Dividing the difference in costs (based on medical consumption (by medical consumption questionnaire(MCQ)) and work productivity (by productivity cost questionnaire(PCQ))) by the difference in quality-adjusted life years (based on EuroQol-5D questionnaire).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Crohn Disease in Remission</condition>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lengthening adalimumab dosing interval</intervention_name>
    <description>Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Lengthening Humira dosing interval</other_name>
    <other_name>Longer adalimumab interval</other_name>
    <other_name>Longer Humira interval</other_name>
    <other_name>Adalimumab dose reduction</other_name>
    <other_name>Humira dose reduction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of colonic and/or distal ileal CD

          -  Sustained steroid-free clinical remission for &gt;9 months whilst being treated with
             adalimumab at a stable dose

          -  Adalimumab dosed at 40 mg sc every 2 weeks

          -  Full clinical response and disease control, all three criteria below need to be
             fulfilled prior to enrollment:

               -  Absence of active inflammatory intestinal or extra-intestinal symptoms, as judged
                  by both patient and physician

               -  Fecal calprotectin (FC) &lt; 150 μg/g and C reactive protein (CRP) &lt;10 mg/L

               -  Harvey Bradshaw Index (HBI) &lt;5

        Exclusion Criteria:

          -  Absence of written informed consent

          -  Concomitant corticosteroid usage

          -  Need for CD-related surgery

          -  Actively draining peri-anal fistula

          -  Pregnancy or lactation

          -  Other significant medical conditions that might interfere with this study (such as
             current/recent malignancy, immunodeficiency syndromes and psychiatric illness)

          -  Impossibility to measure outcomes, e.g. planned relocation, language issues, short
             life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Hoentjen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. dr. van der Woude, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Smits, MD</last_name>
    <phone>0031248186626</phone>
    <email>lisa.smits@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renske Pauwels, MD</last_name>
    <phone>0031650033986</phone>
    <email>r.pauwels@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>PO box 9101, 6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Hoentjen, MD, PhD</last_name>
      <phone>0031248186626</phone>
      <email>frank.hoentjen@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <state>Noord-Brabant</state>
        <zip>PO box 90153, 5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drs. Römkens, MD</last_name>
      <email>t.romkens@jbz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>PO box 90157, 4800 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Bodelier, MD, PhD</last_name>
      <email>ABodelier@amphia.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <state>Noord-Brabant</state>
        <zip>PO box 707, 5400 AS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gisbertz, MD, PhD</last_name>
      <phone>0031413402307</phone>
      <email>i.gisbertz@bernhoven.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. De Boer, MD, PhD</last_name>
      <email>KHN.deBoer@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <zip>PO box 444, 3300 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Wolfhagen, MD, PhD</last_name>
      <email>F.Wolfhagen@asz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 10900, 3004 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. West, MD, PhD</last_name>
      <email>R.West@Franciscus.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 2040, 3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Prof. dr. van der Woude, MD, PhD</last_name>
      <email>c.vanderwoude@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>PO box 5009, 3008 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. ter Borg, MD, PhD</last_name>
      <email>pcj.ter.borg@ikazia.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>003650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mallant, MD, PhD</last_name>
      <email>RMallant@Flevoziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AmsterdamUMC - location AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Löwenberg, MD, PhD</last_name>
      <email>m.lowenberg@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Jansen, MD, PhD</last_name>
      <email>J.M.Jansen@olvg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Jansen, MD, PhD</last_name>
      <email>S.Jansen@rdgg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Boekema, MD, PhD</last_name>
      <email>P.boekema@mmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Russel, MD, PhD</last_name>
      <email>M.Russel@mst.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zuyderland ziekenhuis</name>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Romberg-Camps, MD, PhD</last_name>
      <email>m.camps@zuyderland.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186606</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Kuijvenhoven, MD, PhD</last_name>
      <email>kuyvenhoven@spaarnegasthuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. van der Meulen, MD, PhD</last_name>
      <email>ae.meulen@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Renske Pauwels, MD</last_name>
      <phone>0031650033986</phone>
      <email>r.pauwels@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Pierik, MD, PhD</last_name>
      <email>m.pierik@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Tan, MD, PhD</last_name>
      <email>a.tan@cwz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Lutgens, MD, PhD</last_name>
      <email>m.lutgens@etz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>PO box 85500, 3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Oldenburg, MD, PhD</last_name>
      <email>boldenbu@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smits, MD</last_name>
      <phone>0031248186626</phone>
      <email>lisa.smits@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.zonmw.nl/nl/over-zonmw/innovatie-in-de-zorg/programmas/project-detail/goed-gebruik-geneesmiddelen/lengthening-adalimumab-dosing-interval-in-quiescent-crohns-disease-patients-the-ladi-study/</url>
    <description>Dutch organisation for healthcare research and innovation (ZonMW)</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adalimumab</keyword>
  <keyword>anti-tumor necrosis factor</keyword>
  <keyword>anti-TNF</keyword>
  <keyword>Humira</keyword>
  <keyword>interval lengthening</keyword>
  <keyword>dosing interval</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>antidrug antibodies</keyword>
  <keyword>trough levels</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>cost-effectiveness</keyword>
  <keyword>dose reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

